Acesion, targeting first new approach to AF in decades, hits primary endpoint in midphase trial

Acesion Pharma has early clinical evidence that its new approach to treating atrial fibrillation works. In a phase 2 clinical trial, recipients of the biotech’s first-in-class ion channel inhibitor experienced a return to normal heart rhythm, boosting the prospects of a mechanism that could be the first new approach to afib in 20 years.